FDA Broadens the Use of Risankizumab Drug in Psoriasis

The Amerika Gıda ve İlaç Dairesi (FDA) has significantly expanded the approved use of the drug risankizumab (commercially known as Skyrizi).

According to a statement made by the company AbbVie, this drug, used in the treatment of plaque-type psoriasis and psoriatic arthritis, can now also be used in children aged 6 and over. This decision means an…